Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00133458 |
This study will enroll 120 individuals diagnosed with subarachnoid cysticercosis, a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium. Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite. This study will determine if two months of albendazole (ABZ) therapy is better than one-month. The study will last 3 years.
Condition | Intervention | Phase |
---|---|---|
Subarachnoid Cysticercosis |
Drug: Albendazole |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized, Double Blind Comparison of Two Lenghts of Albendazole Therapy for Subarachnoid Cysticercosis |
Estimated Enrollment: | 120 |
Estimated Study Completion Date: | June 2007 |
This is a randomized, double blind comparison of two lengths of albendazole thereapy for subarachnoid cysticercosis. It will enroll 120 individuals, male and female age 18 to 65, and diagnosed with subarachnoid cysticercosis, a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium. Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite. This study will determine if two months of albendazole (ABZ) therapy is better than one-month. The study will last 3 years.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Brazil | |
Facultad de Medicina de Riberao | |
Riberao Preto, Brazil, 14020-380 | |
Colombia | |
Instituto Neurologico de Antioquia | |
Medellin, Colombia | |
Ecuador | |
Neurology Service, Hospital -Clinica Kennedy | |
Guayaquil, Ecuador | |
Peru | |
Universidad Peruana Cayetano Heredia | |
Lima, Peru |
Study ID Numbers: | 04-003 |
Study First Received: | August 19, 2005 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00133458 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Albenza, Subarachnoid cysticercosis |
Albendazole Central Nervous System Infections Tubulin Modulators Central Nervous System Diseases Cysticercosis Anthelmintics |
Parasitic Diseases Taeniasis Antimitotic Agents Neurocysticercosis Helminthiasis |
Anti-Infective Agents Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Central Nervous System Helminthiasis Neurocysticercosis Central Nervous System Parasitic Infections Albendazole Antiparasitic Agents Therapeutic Uses Cysticercosis Parasitic Diseases Taeniasis |
Helminthiasis Antiplatyhelmintic Agents Nervous System Diseases Mitosis Modulators Central Nervous System Diseases Anthelmintics Antimitotic Agents Pharmacologic Actions Anticestodal Agents Central Nervous System Infections Tubulin Modulators Cestode Infections |